WELL Health Technologies beats top-line estimates; reaffirms FY25 outlook

* WELL Health Technologies press release [https://seekingalpha.com/pr/20200763-well-health-reports-record-revenue-adjusted-ebitda-and-adjusted-net-profit-in-q2minus-2025] (OTC:WHTCF [https://seekingalpha.com/symbol/WHTCF]): Q2 Non-GAAP EPS of $0.10.
* Revenue of $356.7M (+56.9% Y/Y) beats by $100.2M.
* WELL achieved record Adjusted EBITDA(1) of $49.7 million in Q2-2025, an increase of 231% compared to Q2-2024. Excluding the impact from CM Deferrals, Adjusted EBITDA would have been $40.0 million in Q2-2025.
* WELL REAFFIRMS ITS PREVIOUSLY PROVIDED ANNUAL GUIDANCE for annual revenue between $1.40 billion to $1.45 billion VS. CONSENSUS OF $1.03B, with Adjusted EBITDA between $190 million to $210 million. Excluding CM Deferrals, WELL reaffirms guidance for annual revenue between $1.35 billion to $1.40 billion and Adjusted EBITDA between $140 million and $160 million, In both cases, WELL is pleased to improve guidance to the upper half of the guidance ranges noted above.

MORE ON WELL HEALTH TECHNOLOGIES

* WELL Health: Divestitures And Canadian Focus Could Trigger A Valuation Re-rating [https://seekingalpha.com/article/4789641-well-health-divestitures-canadian-focus-could-trigger-valuation-re-rating]
* Historical earnings data for WELL Health Technologies [https://seekingalpha.com/symbol/WELL:CA/earnings]
* Financial information for WELL Health Technologies [https://seekingalpha.com/symbol/WELL:CA/income-statement]